Web31 May 2024 · This finding is of significance because at present LCNEC patients are often treated like SCLC. However, the universal genomic SCLC biomarker of TP53 and RB1 co-mutation was only found in 40% of their cohort. Since then various other scientists have looked into molecular profiling of LCNEC with markedly discordant results. WebBackground: Progastrin-releasing peptide (proGRP) is a recently identified biomarker of small cell lung cancer (SCLC). We evaluated the usefulness of plasma proGRP level as a tumor marker for diagnosis and treatment monitoring in patients with SCLC.
Frontiers Prevalence of TP-53/Rb-1 Co-Mutation in Large Cell ...
WebBlood-based next-generation sequencing assays of circulating tumor DNA (ctDNA) have the ability to detect tumor-associated mutations in patients with SCLC. We sought to characterize the relationship between ctDNA mean variant allele frequency (VAF) and radiographic total-body tumor volume (TV) in patients with SCLC. We identified matched … Web1 Jul 2004 · By contrast, abnormal ProGRP results are found in 60–70% and in 75–90% of SCLC patients with local and extensive disease, respectively. ProGRP is a more sensitive biomarker than is neuron-specific enolase (NSE) for SCLC, but thus far has not been found in multivariate analysis to have independent prognostic significance. croatia cruises july 2023
The role of Schlafen 11 (SLFN11) as a predictive …
Web16 Dec 2024 · In addition to SCLC, SLFN11 has also shown promise as a predictive biomarker of response in ovarian and prostate cancer. 2, 13 Nogales and colleagues … Web2 Feb 2024 · In this multicenter study, we investigated the genomic characteristics of LCNEC, SCLC, and carcinoid tumors with targeted next-generation sequencing (NGS) to further compare the genomic landscapes among different histological subtypes of pNET and to explore genomic prognostic and actionable biomarkers for pNET in this cohort. WebThe small cell (OriGene Technologies), expressed in Escherichia coli (Promega) lung cancer (SCLC) biomarker progastrin releasing peptide using pGEX-6P-3 constructs (GE Healthcare) and puri ed as (ProGRP) was used as model compound and immunocapture described elsewhere.16 The concentration of the ProGRP stock MS of intact ProGRP as benchmark. croatia cost of travel